{
    "clinical_study": {
        "@rank": "167",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04344782"
        },
        "id_info": {
            "org_study_id": "APHP200389-7",
            "nct_id": "NCT04344782"
        },
        "brief_title": "Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin\u00ae/Zeribev\u00ae) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",
        "acronym": "CORIMMUNO-BEVA",
        "official_title": "Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris",
                "agency_class": "Other"
            }
        },
        "source": "Assistance Publique - H\u00f4pitaux de Paris",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Bevacizumab, ZERIBEV\u00ae (Pfizer)/AVASTIN\u00ae (Roche) 25 mg/ml \u00ae, is a recombinant humanised\n      monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected\n      with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU.\n\n      This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN\u00ae/ ZERIBEV\u00ae\n      (bevacizumab) COVID-19 patients hospitalized in conventional units.\n\n      This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of\n      AVASTIN\u00ae/ ZERIBEV\u00ae (bevacizumab) alone versus standard of care (SoC) in patients hospitalized\n      in conventional units."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 15, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "November 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Proportion of surviving patients without need for intubation for respiratory support",
            "time_frame": "day 14"
        },
        "secondary_outcome": [
            {
                "measure": "Saturation of Oxygen in the blood (SaO2)",
                "time_frame": "day 14",
                "description": "value of a healthy individual occurs between 95 - 100"
            },
            {
                "measure": "Arterial oxygen partial pressure (paO2)",
                "time_frame": "day 14",
                "description": "value of a healthy individual occurs between 75-100 mmHg"
            },
            {
                "measure": "Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)",
                "time_frame": "day 14",
                "description": "Normal level should be >500 Index of severity of acute respiratory distress syndrome (ARDS) mild if 200-300 moderate if 100-200 severe if < 200"
            },
            {
                "measure": "CT-scan score",
                "time_frame": "day 14"
            },
            {
                "measure": "dyspnea",
                "time_frame": "day 28",
                "description": "measured on an visual analog scale (VAS), ranging from 0 (no dyspnea) to 10 (major dyspnea)"
            },
            {
                "measure": "overall survival",
                "time_frame": "day 14 and 28"
            },
            {
                "measure": "admissionn to the intensive care unit (ICU)",
                "time_frame": "day 14 and day 28"
            },
            {
                "measure": "incidence of mechanical ventilation",
                "time_frame": "day 14 and day 28"
            },
            {
                "measure": "hospital length of stay",
                "time_frame": "day 28"
            },
            {
                "measure": "incidence of adverse event",
                "time_frame": "day 28"
            },
            {
                "measure": "VEGF plasma concentration",
                "time_frame": "day 28"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "130"
        },
        "condition": "COVID19 Pneumonia",
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab",
                "arm_group_type": "Experimental"
            },
            {
                "arm_group_label": "Standard of Care",
                "arm_group_type": "No Intervention"
            }
        ],
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Bevacizumab Injection",
            "description": "Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.",
            "arm_group_label": "Bevacizumab"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients Requiring more than 3L/min of oxygen\n\n          -  WHO progression scale = 5 to 8\n\n        Exclusion Criteria:\n\n          -  Patients in 9 WHO progression class\n\n          -  Patients with exclusion criteria to the CORIMUNO-19 cohort.\n\n          -  Hypersensitivity to Bevacizumab or to any of their excipients.\n\n          -  Pregnancy\n\n          -  Active Cancer with undergoing treatment\n\n          -  Oxygen patient requiring long-term oxygen before hospitalization\n\n          -  Patient already included in a therapeutic trial; however, inclusion should be\n             discussed case by case with the trial coordinator.\n\n          -  Contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous\n             or arterial thromboembolic disease and recent surgery.\n\n          -  Hypersensitivity to the active substance or one of the excipients"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Jacques Cadranel, MD PhD",
            "phone": "1 56 01 66 73",
            "phone_ext": "33",
            "email": "jacques.cadranel@aphp.fr"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 9, 2020",
        "study_first_submitted_qc": "April 12, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "last_update_submitted": "April 12, 2020",
        "last_update_submitted_qc": "April 12, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": "Pneumonia"
        },
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        },
        "patient_data": {
            "sharing_ipd": "Undecided"
        }
    }
}